









市場行情
/
股票
/
nasdaq-atai
/

ATAI Life Sciences NV

ATAI

4.070USD

-0.120-2.86%

收盤 12/26, 16:00（美東）報價延遲15分鐘

978.58M總市值

虧損本益比TTM



ATAI Life Sciences NV

4.070

-0.120-2.86%

概覽公司財務分析

概覽

公司

財務

分析

關於 ATAI Life Sciences NV 公司

Atai Beckley NV, formerly ATAI Life Sciences NV, is a clinical-stage biopharmaceutical company. The Company focused on developing treatments for mental health disorders. The Company's pipeline includes psychedelic and non-psychedelic compounds targeting depression, anxiety, and other unmet needs in psychiatry.

ATAI Life Sciences NV簡介



公司代碼ATAI

公司名稱ATAI Life Sciences NV

上市日期Jun 18, 2021

CEORao (Srinivas G)

員工數量54

證券類型Ordinary Share

年結日Jun 18

公司地址Prof. J.H.Bavincklaan 7

城市AMSTELVEEN

上市交易所NASDAQ OMX - NASDAQ BASIC

國家Netherlands

郵編1183 AT

電話31207932536

網址https://www.atai.com/

公司代碼ATAI

上市日期Jun 18, 2021

CEORao (Srinivas G)

ATAI Life Sciences NV公司高管



名稱

名稱/職務

職務

持股

持股變動

Dr. Glenn Frank Short, Ph.D.

Chief Scientific Officer

42.33K

+84.10%

Ms. Andrea Heslin Smiley

Independent Supervisory Director

4.67K

Dr. Amir Kalali

Independent Supervisory Director

Dr. Kevin James Craig, M.D.

Chief Medical Officer

Ms. Anne Johnson

Chief Financial Officer

Dr. Gerd G. Kochendoerfer

Chief Operating Officer

Mr. Christian Angermayer

Chairman of the Supervisory Board

Ms. Sabrina Martucci Johnson

Independent Supervisory Director

Dr. Srinivas Rao, M.D., Ph.D.

Chief Executive Officer, Co-Founder, Interim Managing Director

Dr. Laurent Fischer, M.D.

Independent Supervisory Director

名稱

名稱/職務

職務

持股

持股變動

Dr. Glenn Frank Short, Ph.D.

Chief Scientific Officer

42.33K

+84.10%

Ms. Andrea Heslin Smiley

Independent Supervisory Director

4.67K

Dr. Amir Kalali

Independent Supervisory Director

Dr. Kevin James Craig, M.D.

Chief Medical Officer

Ms. Anne Johnson

Chief Financial Officer

Dr. Gerd G. Kochendoerfer

Chief Operating Officer

收入明細

由於公司未披露，未能獲取相關數據

由於公司未披露，未能獲取相關數據

業務

地區

由於公司未披露，未能獲取相關數據

股東統計

更新時間: 12月12日週五

持股股東

股東類型

持股股東

佔比

Apeiron Investment Group Ltd

15.20%

Feilding-Mellen (Cosmo)

2.12%

UBS Financial Services, Inc.

1.72%

Adage Capital Management, L.P.

1.50%

Brand (Florian Olaf)

1.39%

其他

78.08%

持股股東

佔比

Apeiron Investment Group Ltd

15.20%

Feilding-Mellen (Cosmo)

2.12%

UBS Financial Services, Inc.

1.72%

Adage Capital Management, L.P.

1.50%

Brand (Florian Olaf)

1.39%

其他

78.08%

股東類型

持股股東

佔比

Family Office

15.21%

Investment Advisor

4.61%

Hedge Fund

4.11%

Individual Investor

3.70%

Investment Advisor/Hedge Fund

1.83%

Research Firm

1.23%

Bank and Trust

0.40%

Private Equity

0.39%

Endowment Fund

0.20%

其他

68.33%

機構持股



更新時間: 12月8日週一

報告期間

機構數

持股數

持股佔比

持股變動

2025Q4

218

45.07M

10.88%

+16.45K

2025Q3

249

45.57M

19.55%

+12.66M

2025Q2

225

29.96M

14.58%

+6.94M

2025Q1

223

23.03M

12.83%

-2.41M

2024Q4

236

15.60M

13.86%

+2.09M

2024Q3

236

13.53M

16.71%

-545.79K

2024Q2

246

14.10M

16.43%

-259.20K

2024Q1

244

14.41M

17.26%

-14.24M

2023Q4

251

15.93M

17.75%

-1.57M

2023Q3

259

17.69M

19.30%

-562.50K

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

Apeiron Investment Group Ltd

55.20M

25.75%

+2.37M

+4.48%

Sep 30, 2025

UBS Financial Services, Inc.

7.08M

3.3%

+3.21M

+83.06%

Jun 30, 2025

Adage Capital Management, L.P.

5.43M

2.54%

+5.43M

Jun 30, 2025

Brand (Florian Olaf)

5.04M

2.35%

-250.00K

-4.73%

Sep 15, 2025

Morgan Stanley Investment Management Inc. (US)

1.85M

0.86%

+4.04K

+0.22%

Jun 30, 2025

Citadel Advisors LLC

1.18M

0.55%

+1.15M

+4612.14%

Jun 30, 2025

ARK Investment Management LLC

1.55M

0.72%

-59.62K

-3.71%

Aug 31, 2025

持股ETF



更新時間: 12月6日週六

機構名稱

佔比

AdvisorShares Psychedelics ETF

17.55%

ARK Genomic Revolution ETF

1.6%

Invesco NASDAQ Future Gen 200 ETF

0.69%

Even Herd Long Short ETF

0.14%

Avantis US Small Cap Equity ETF

0.08%

First Trust IPOX Europe Equity Opportunities ETF

0.06%

SPDR S&P International Small Cap ETF

0.05%

Fidelity Nasdaq Composite Index ETF

ProShares Ultra Nasdaq Biotechnology

Avantis US Equity ETF

AdvisorShares Psychedelics ETF

佔比17.55%

ARK Genomic Revolution ETF

佔比1.6%

Invesco NASDAQ Future Gen 200 ETF

佔比0.69%

Even Herd Long Short ETF

佔比0.14%

Avantis US Small Cap Equity ETF

佔比0.08%

First Trust IPOX Europe Equity Opportunities ETF

佔比0.06%

SPDR S&P International Small Cap ETF

佔比0.05%

Fidelity Nasdaq Composite Index ETF

佔比0%

ProShares Ultra Nasdaq Biotechnology

佔比0%

Avantis US Equity ETF

佔比0%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股



公告日期

類型

比率

暫無數據

公告日期

類型

比率

暫無數據

常見問題

ATAI Life Sciences NV的前五大股東是誰？



ATAI Life Sciences NV的前五大股東如下：
Apeiron Investment Group Ltd
持有股份：55.20M
佔總股份比例：25.75%。
UBS Financial Services, Inc.
持有股份：7.08M
佔總股份比例：3.30%。
Adage Capital Management, L.P.
持有股份：5.43M
佔總股份比例：2.54%。
Brand (Florian Olaf)
持有股份：5.04M
佔總股份比例：2.35%。
Morgan Stanley Investment Management Inc. (US)
持有股份：1.85M
佔總股份比例：0.86%。